Official Launch | iCyagen Digital Research Service Platform — Empowering Intelligent Research Across

Drawing on two decades of expertise in biomedical research, Cyagen Biosciences has developed the iCyagen Digital Research Service Platform to address the field's core research pain points and R&D needs. The platform will be officially launched in full on September 1, 2026. Focusing on the entire biomedical research workflow, iCyagen adopts a digital, intelligent, and integrated service model to overcome the limitations of traditional research approaches, providing researchers with efficient, professional, and convenient one-stop research solutions that comprehensively support life-science innovation and industry upgrading. Click to learn more about the iCyagen platform.

In traditional biomedical research, scientists have long struggled with numerous pain points: research data is fragmented and siloed, cross-database retrieval is cumbersome and inefficient, general-purpose AI tools lack domain expertise and are prone to inaccuracies, and research tools operate in isolation, forcing repeated switching across multiple platforms. Experimental design, data analysis, and model development are time-consuming and labor-intensive, severely undermining R&D efficiency. To tackle these widespread bottlenecks, Cyagen Biosciences leveraged two decades of accumulated technical know-how and a vast research knowledge base to innovatively build the iCyagen Digital Research Service Platform—reimagining the biomedical research paradigm to make complex work simpler, faster, and more precise.

iCyagen is among the first in the industry to launch an enterprise-grade, multi-expert intelligent Agent matrix purpose-built for the biomedical vertical. Unlike generic AI tools, the platform draws on Cyagen's proprietary research knowledge base accumulated over two decades and combines knowledge-graph and large-model technologies to address the "hallucination" problem inherent in general-purpose AI at its root.

The intelligent Agents precisely understand specialized biomedical research needs and automatically break down complex tasks, covering high-frequency, core scenarios such as gene-editing protocol design, intelligent diagnosis of abnormal animal symptoms with care recommendations, and cell and animal experiments. They directly deliver actionable, reusable expert research plans, replacing large volumes of repetitive, routine work and substantially reducing trial-and-error and time costs.

To solve the industry-wide challenge of independent, fragmented, and weakly interconnected biological databases, iCyagen built an integrated research database unifying genes, diseases, mutations, and models. By connecting the underlying architectures of the four core databases, it achieves deep, interconnected data sharing.

The platform supports millisecond-level cross-database intelligent search along with intuitive data-visualization features, providing researchers with high-granularity, high-credibility, fully traceable bioinformatics support. It covers all needs—from basic data queries and research provenance analysis to evidence for project studies—fully eliminating the hassle of multi-platform searching and data consolidation. Experience the four-in-one data search now.

To meet the precise needs of specialized biomedical research scenarios, the platform offers several bioinformatics-plus-AI professional tools developed in-house by Cyagen. Targeting niche R&D challenges, they streamline research workflows, enabling professional data analysis and sequence design without complex operations:

Focused on base-mutation and mRNA-splicing research, it accurately predicts whether base mutations alter mRNA splicing sites, and provides comprehensive, fine-grained analysis and visualization of mutation effects and abnormal-splicing mechanisms. It delivers precise data support for gene-function studies, exploration of mutation pathogenicity mechanisms, and gene-editing experiment design. Try the tool.

Focused on antisense oligonucleotide (ASO) drug development and gene-regulation research, it precisely computes core pairing metrics—binding affinity, match degree, and stability—between an ASO and its target sequence, intelligently screening high-quality, high-potential candidate sequences. This effectively improves ASO sequence-design efficiency and success rates, accelerating early-stage drug R&D and gene-regulation experiments. Try the tool.

The platform newly integrates an AI-driven pathogenicity prediction model built on deep-learning algorithms—a professional mutation-analysis tool suited to research, clinical, and educational scenarios. It rapidly and accurately predicts the pathogenicity probability of variant sites—including single-base substitutions, insertions, and deletions in the human genome—and assesses the likelihood that a mutation causes serious disease.

With a simple, one-click operation that outputs precise analysis results, it provides efficient, reliable, reusable data-analysis support for disease-mechanism research, genetic-disorder analysis, clinical adjunctive evaluation, and teaching case studies, filling the gap in intelligent pathogenicity analysis of gene mutations. Try the tool.

From basic retrieval of gene, disease, mutation, and model data, to professional experimental protocol design for gene editing, animal studies, and cell experiments; from auxiliary support for research outputs such as papers and patents, to antibody-sequence analysis, protein-structure prediction, and drug-development optimization—the iCyagen platform delivers full-scenario, end-to-end coverage of biomedical research.

The platform fundamentally breaks the traditional research trap of "constant platform switching, juggling multiple tools, hard-to-share data, and unprofessional AI." Centered on an integrated data foundation, an intelligent expert matrix, and proprietary specialized tools, it simplifies research workflows, lowers the R&D barrier, shortens development cycles, and cuts research costs—freeing scientists from tedious, repetitive tasks so they can focus on core scientific exploration and innovation.

On September 1, 2026, the iCyagen Digital Research Service Platform will officially open for use. Moving forward, Cyagen Biosciences will continue to deepen its commitment to digital biomedical research—iteratively enhancing platform functions, expanding research scenarios, and improving the user experience—empowering industry development through technological innovation.

We sincerely invite researchers everywhere to log in and explore this new paradigm of intelligent research. We also eagerly look forward to your valuable feedback and suggestions, which will help iCyagen keep improving and evolving into a more tailored, professional, and efficient digital biomedical research platform—working hand in hand with industry peers to unlock the limitless possibilities of the life sciences.